We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

31 hedge funds and large institutions have $163M invested in Inhibikase Therapeutics in 2024 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

14,452% more capital invested

Capital invested by funds: $1.12M → $163M (+$162M)

667% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 3

182% more funds holding

Funds holding: 11 → 31 (+20)

62.99% more ownership

Funds ownership: 11.53% → 74.53% (+63%)

Holders
31
Holders Change
+20
Holders Change %
+181.82%
% of All Funds
0.41%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
23
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCV
Sands Capital Ventures
Virginia
+$27.3M
2
SCM
Soleus Capital Management
Connecticut
+$15.8M
3
FFM
Fairmount Funds Management
Pennsylvania
+$15.3M
4
CC
Commodore Capital
New York
+$14.8M
5
PA
Perceptive Advisors
New York
+$14.8M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$814K
2
Renaissance Technologies
Renaissance Technologies
New York
-$25.9K
3
TRCT
Tower Research Capital (TRC)
New York
-$5.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCV
1
Sands Capital Ventures
Virginia
$35.6M +$27.3M +10,950,000 New
SCM
2
Soleus Capital Management
Connecticut
$20.6M +$15.8M +6,325,000 New
FFM
3
Fairmount Funds Management
Pennsylvania
$19.9M +$15.3M +6,125,000 New
CC
4
Commodore Capital
New York
$19.3M +$14.8M +5,925,000 New
PA
5
Perceptive Advisors
New York
$19.3M +$14.8M +5,925,000 New
ACM
6
ADAR1 Capital Management
Texas
$16.6M +$12.7M +5,103,005 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.23M +$7.04M +2,821,921 +16,873%
NCM
8
Nantahala Capital Management
Connecticut
$7.12M +$5.46M +2,190,000 New
Blackstone Inc
9
Blackstone Inc
New York
$6.73M +$5.17M +2,070,684 New
SCM
10
Stonepine Capital Management
Oregon
$3.68M +$2.82M +1,132,388 New
BlackRock
11
BlackRock
New York
$1.09M +$837K +335,460 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.05M +$681K +272,813 +545%
Millennium Management
13
Millennium Management
New York
$462K +$355K +142,209 New
William Blair & Company
14
William Blair & Company
Illinois
$439K +$22K +8,833 +7%
Barclays
15
Barclays
United Kingdom
$273K +$210K +84,000 New
Citigroup
16
Citigroup
New York
$251K +$192K +77,100 New
Northern Trust
17
Northern Trust
Illinois
$208K +$160K +64,011 New
OAC
18
OMERS Administration Corp
Ontario, Canada
$177K +$136K +54,600 New
HF
19
HRT Financial
New York
$150K +$116K +46,416 New
Goldman Sachs
20
Goldman Sachs
New York
$143K +$110K +43,952 New
State Street
21
State Street
Massachusetts
$136K +$79.3K +31,800 +315%
AGM
22
Alpine Global Management
New York
$96.5K +$74K +29,684 New
Squarepoint
23
Squarepoint
New York
$92.3K +$70.9K +28,411 New
UBS Group
24
UBS Group
Switzerland
$89.5K +$56.5K +22,653 +465%
CC
25
Caxton Corporation
New Jersey
$53.3K +$40.9K +16,393 New
1
2

IKT Hedge Fund Activity: Q4 2024 in Review

31 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q4 2024, worth a combined $163M — up 14,452% from $1.12M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new IKT positions and 3 closed out — a net gain of 20 holders — while 7 added to existing stakes and 0 trimmed.

The largest buyer was Sands Capital Ventures, opening a new position worth an estimated $27.3M. The largest seller was Armistice Capital, exiting entirely with an estimated $814K sold.

  • 31 institutional investors held Inhibikase Therapeutics (IKT) as of Q4 2024, up from 11 in Q3 2024.
  • Funds reported $163M of Inhibikase Therapeutics stock for Q4 2024, up 14,452% quarter-over-quarter.
  • 23 funds opened new Inhibikase Therapeutics positions in Q4 2024 and 3 closed out, a net change of +20 holders.
  • The largest Inhibikase Therapeutics buyer in Q4 2024 was Sands Capital Ventures, an estimated $27.3M added.
  • The largest Inhibikase Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $814K sold.

Based on aggregated 13F filings for Q4 2024.